Evidence map›Paper›PMID 38785726›Full record

ArticleBiosensors2024

The Construction and Application of a New Screening Method for Phosphodiesterase Inhibitors.

Chunhua Gao, Zhe Wang, Xiaojing Liu, Rongzhen Sun, Shengyao Ma, Zongchen Ma, Qi Wang, Guoqiang Li, Han-Ting Zhang

Abstract read
In one paragraph

Article in Biosensors, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Chunhua GaoDepartment of Pharmacology, School of Pharmacy, Qingdao University, Qingdao 266073, China.
Zhe WangDepartment of Pharmacology, School of Pharmacy, Qingdao University, Qingdao 266073, China.
Xiaojing LiuDepartment of Pharmacology, School of Pharmacy, Qingdao University, Qingdao 266073, China.
Rongzhen SunDepartment of Pharmacology, School of Pharmacy, Qingdao University, Qingdao 266073, China.
Shengyao MaDepartment of Pharmacology, School of Pharmacy, Qingdao University, Qingdao 266073, China.
Zongchen MaKey Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University, Qingdao 266003, China.ORCID 0000-0001-7248-2502
Qi WangDepartment of Pharmacology, School of Pharmacy, Qingdao University, Qingdao 266073, China.ORCID 0000-0003-4591-2129
Guoqiang LiKey Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University, Qingdao 266003, China.ORCID 0000-0003-3223-4007
Han-Ting ZhangDepartment of Pharmacology, School of Pharmacy, Qingdao University, Qingdao 266073, China.

Funding

Key Program of Brain Science and Brain-Like Intelligence Technology of the China Ministry of Science and Technology STI2030-Major Projects 2021ZD0202904Key Project by Qingdao Bureau of Sciences and Technology Grand No. 22-3-3-hygg-25-hyNational Key R&D Program for Young Scientists of China Grant No. 2022YFC2804500National Natural Science Foundation of China Grant No. 82273848
6 · The paper itself

Abstract

Phosphodiesterases (PDEs), a superfamily of enzymes that hydrolyze cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), are recognized as a therapeutic target for various diseases. However, the current screening methods for PDE inhibitors usually experience problems due to complex operations and/or high costs, which are not conducive to drug development in respect of this target. In this study, a new method for screening PDE inhibitors based on GloSensor technology was successfully established and applied, resulting in the discovery of several novel compounds of different structural types with PDE inhibitory activity. Compared with traditional screening methods, this method is low-cost, capable of dynamically detecting changes in substrate concentration in live cells, and can be used to preliminarily determine the type of PDEs affected by the detected active compounds, making it more suitable for high-throughput screening for PDE inhibitors.

Indexed as

Phosphodiesterase InhibitorsBiosensing TechniquesCyclic AMPCyclic GMPDrug Evaluation, PreclinicalHigh-Throughput Screening AssaysHumansPhosphoric Diester HydrolasesCyclic AMPCyclic GMPPhosphodiesterase InhibitorsPhosphoric Diester Hydrolasescompoundscyclic adenosine monophosphatecyclic guanosine monophosphateinhibitorsphosphodiesterasesscreening methods

Identifiers

PMID38785726
PMCPMC11117652

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.